BioSpace News Archive

Solasia Pharma K.K. officially announced that an organoarsenic drug “DARVIAS® Injection 135mg” has been launched today in Japan for use in relapsed or refractory Peripheral T-Cell Lymphoma.

Pharvaris announced that the U.S. Food and Drug Administration verbally informed Pharvaris that, based on its review of nonclinical data, the agency is placing a clinical hold on the clinical trials of PHA121 in the U.S. under two Pharvaris Investigational New Drug applications for the treatment of HAE.

Attralus, Inc. today announced that new data across the Company’s amyloidosis portfolio will be presented in both oral and poster presentations at the XVIII International Symposium on Amyloidosis (ISA) by Attralus, the University of Tennessee Graduate School of Medicine and the Brigham and Women’s Hospital.

Bright Peak Therapeutics today announced the appointment of Jon Wigginton, M.D., as its President of Research and Development.

Cara Therapeutics, Inc. today announced data from the KOMFORT Phase 2 clinical trial evaluating oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica will be presented during a late-breaking news session at the 31st European Academy.

Fennec Pharmaceuticals Inc. today announced it has completed the first closing of US$5 million of senior secured promissory notes under our previously announced investment agreement with Petrichor Healthcare Capital Management.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the Phase 2 PREVAIL study of TNX-102 SL1 as a potential treatment for a subset of patients with Long COVID syndrome (Long COVID) whose symptoms overlap with fibromyalgia.

XORTX Therapeutics Inc. is pleased to announce positive topline results from its Pharmacokinetics Bridging Study – XRX-OXY-101 – Part 2– (“Part 2”) showing a substantial increase in oral bioavailability of XORTX’s proprietary oxypurinol formulation provided with food compared to the fasted state.

Travere Therapeutics, Inc. (NASDAQ: TVTX) and CSL Vifor today announced that the EMA has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the treatment of Nephropathy.

Management team will host R&D day on Thursday, September 15, from 10am ET in New York City with Key Opinion Leader (KOL) participation.